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Abstract
Background—The melanocortin (MC) system is composed of peptides that are cleaved from the
polypeptide precursor proopiomelanocortin (POMC). Recent evidence shows that chronic
exposure to ethanol significantly blunts central MC peptide immunoreactivity and MC receptor
(MCR) agonists protect against high ethanol intake characteristic of C57BL/6J mice. Here we
assessed the role of the MC-4 receptor (MC4R) in voluntary ethanol intake and in modulating the
effects of the non-selective MCR agonist melanotan-II (MTII) on ethanol consumption.
Methods—To assess the role of the MC4R, MC4R knockout (Mc4r-/-) and littermate wildtype
(Mc4r+/+) mice on a C57BL/6J background were used. Voluntary ethanol (3, 5, 8, 10, 15, and
20%, v/v) and water intake were assessed using standard two-bottle procedures. In separate
experiments, Mc4r-/- and Mc4r+/+ mice were given intracerebroventricular (i.c.v.) infusion of
MTII (0, 0.5, or 1.0 μg/1 μl) or intraperitoneal (i.p.) injection of MTII (0 or 5 mg/kg/5 ml). The
effects of MTII (0 or 0.5 μg/1 μl, i.c.v.) on 10% sucrose and 0.15% saccharin intake were assessed
in C57BL/6J mice.
Results—Mc4r-/- mice showed normal consumption of ethanol over all concentrations tested.
I.c.v. infusion of MTII significantly reduced ethanol drinking in Mc4r+/+ mice, but failed to
influence ethanol intake in Mc4r-/- mice. When administered in an i.p. injection, MTII
significantly reduced ethanol drinking in both Mc4r-/- and Mc4r+/+ mice. MTII attenuated
consumption of caloric (ethanol, sucrose and food) and non-caloric (saccharin) reinforcers.
Conclusions—When given centrally, the MCR agonist MTII reduced ethanol drinking by
signaling through the MC4R. On the other hand, MTII-induced reduction of ethanol drinking did
not require the MC4R when administered peripherally. Together, the present observations show
that the MC4R is necessary for the central actions of MCR agonists on ethanol drinking, and that
MTII blunts the consumption natural reinforcers, regardless of caloric content, in addition to
ethanol.
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The Melanocortin (MC) system is composed of peptides that are cleaved from the
polypeptide precursor pro-opiomelanocortin (POMC). Central MC peptides are produced by
neurons within the hypothalamic arcuate nucleus, the nucleus of the solitary tract, and the
medulla (Crine et al., 1978; Dores et al., 1986; Hadley and Haskell-Luevano, 1999;
Jacobowitz and O'Donohue, 1978; O'Donohue and Dorsa, 1982) and include
adrenocorticotropic hormone (ACTH), α-melanocyte-stimulating hormone (α-MSH), β-
MSH, and γ-MSH (Hadley and Haskell-Luevano, 1999). Due to a lack of a critical dibasic
site, β-MSH is not processed in rodent brain (Pritchard et al., 2002). MC neuropeptides act
through at least five receptor subtypes, namely MC-1 receptor (MC1R), MC2R, MC3R,
MC4R, and MC5R, all of which couple to heterotrimeric Gs-proteins that stimulate adenylyl
cyclase activity (Hadley and Haskell-Luevano, 1999). MC receptors (MCRs) in the rodent
brain are primarily comprised of the MC3R and MC4R subtypes (Adan and Gispen, 1997),
whereas MC1R and MC5R are detected at low levels and only in limited brain regions while
the MC2R is expressed primarily in the adrenal cortex (Adan and Gispen, 1997; Barrett et
al., 1994; Xia et al., 1995).
It is well established that MCR signaling is involved in the regulation of appetite and energy
homeostasis (Gao and Horvath, 2008). A growing literature suggests that there is
overlapping peptide control of ethanol consumption and feeding behavior (Thiele et al.,
2003; Thiele et al., 2004), which includes recent evidence that MCR signaling modulates
neurobiological responses to ethanol. MCR and α-MSH expression have been identified in
brain regions that modulate the reinforcing properties of ethanol, including the nucleus
accumbens (NAc), ventral tegmental area, the bed nucleus of the stria terminalis, and
amygdala (Bloch et al., 1979; Dube et al., 1978; Jacobowitz and O'Donohue, 1978;
O'Donohue and Jacobowitz, 1980; O'Donohue et al., 1979; Yamazoe et al., 1984). Genetic
and pharmacological evidence implicate the MC system in the control of voluntary ethanol
consumption. Relative to ANA (Alko, Non-Alcohol) rats, AA (Alko, Ethanol) rats,
selectively bred for high ethanol intake, have significantly lower levels of MC3R in the shell
of the NAc, and significantly higher levels of MC3R in the paraventricular, arcuate, and
ventromedial nuclei of the hypothalamus. AA rats also have high levels of MC4R in the
ventromedial nucleus of the hypothalamus (Lindblom et al., 2002). These data suggest that
the high ethanol drinking by AA rats may be mediated, in part, by alterations of central
MCR signaling. Consistent with this hypothesis, intracerebroventricular (i.c.v.) infusion of
the potent non-selective MCR agonist melanotan-II (MTII) significantly reduced voluntary
ethanol drinking by AA rats (Ploj et al., 2002). Similarly, we have found that i.c.v. infusion
of MTII and a selective MC4R agonist reduced ethanol drinking (Navarro et al., 2005;
Navarro et al., 2003), while ventricular infusion of the non-selective MCR antagonist agouti-
related protein (AgRP) significantly increased ethanol drinking (Navarro et al., 2005), by
high ethanol drinking C57BL/6J mice. Consistent with pharmacological data, genetic
deletion of endogenous AgRP reduced ethanol-reinforced lever pressing and binge-like
ethanol drinking in C57BL/6J (Navarro et al., 2009). Ethanol also has direct effects of
central MC and AgRP activity. Thus, chronic exposure to ethanol significantly reduced α-
MSH immunoreactivity in specific regions of the rat brain (Navarro et al., 2008), and acute
administration of ethanol significantly increased AgRP immunoreactivity in the arcuate
nucleus of the hypothalamus of C57BL/6J mice (Cubero et al., 2010).
The MCRs that modulate neurobiological responses to ethanol remain unclear. With respect
to ethanol consumption, we found that MTII was similarly effective at reducing ethanol
intake in both MC3R knock-out (Mc3r-/-) and littermate wild-type (Mc3r+/+) mice (Navarro
et al., 2005). Furthermore, i.c.v. infusion of the highly selective MC4R agonist, cyclo(NH-
CH2-CH2-CO-His-D-Phe-Arg-Trp-Glu)-NH2, dose-dependently reduced ethanol drinking
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by C57BL/6J mice (Navarro et al., 2005). These data suggest that the MC3R does not
modulate MCR agonist-induced reductions of ethanol consumption, and that the MC4R is a
likely candidate. The first goal of the present report was to directly assess the role of the
MC4R. To this end, we examined voluntary ethanol consumption, and the effects of
centrally- and peripherally-administered MTII on ethanol intake, in Mc4r-/- and littermate
Mc4r+/+ mice. The second goal was to further characterize the effects of MTII on
consumption of other caloric (food and sucrose) and non-caloric (saccharin) reinforcers.
Materials and Methods
Animals
The generation of Mc4r-/- mice has been described elsewhere (Huszar et al., 1997). The
Mc4r-/- mice were originally derived on a mixed 129/SvJ × C57BL/6J genetic background
and show increased body weight and feeding behavior beginning at about 3-4 months of age
(Huszar et al., 1997; Ste Marie et al., 2000). For the present work, we backcrossed Mc4r-/-
mice to a C57BL/6J genetic background for 8 generations. Despite the lack of the MC4R,
Mc4r-/- mice show normal brain expression of MC3R mRNA (Rowland et al., 2010).
Littermate knockout and wild-type mice were used, and approximately equal numbers of
male and female mice were used in each treatment condition. Because we have previously
found no sex differences in the effect of MTII on ethanol consumption in C57BL/6J mice
(Navarro et al., 2005), and because of low numbers of male and female mice within each
treatment condition, sex was not included as a factor in analyses described below. The
genetic status of all mice was determined using polymerase chain reaction (PCR)
procedures, and mice were approximately 6 weeks of age at the beginning of experiments.
We also used male C57BL/6J mice that were purchased at 6 weeks of age from Jackson
Laboratory (Bar Harbor ME). Mice were individually housed in polypropylene cages with
corncob bedding and had ad libitum access to water and standard rodent chow (Tekland,
Madison, WI) throughout each experiment. The colony room was maintained at
approximately 22° C with a reverse 12h:12h light:dark cycle with lights off at 10:00 a.m. All
procedures used in the present study were in compliance with the National Institute of
Health guidelines, and all protocols were approved by the University of North Carolina
Institutional Animal Care and Use Committee.
Experiment 1: Two-Bottle Consumption of Ethanol, Sucrose, Saccharin, and Water
Mc4r-/- (n = 8) and Mc4r+/+ (n = 9) mice were tested for voluntary ethanol consumption
using a homecage 2-bottle choice procedure. Over 4-days, mice were given 24-hour access
to 2-bottles on their homecage, one containing tap water and the other containing a 3% (v/v)
ethanol solution. The concentrations of ethanol were then increased to 5, 8, 10, 15, and 20%
every 4-days. The positions of the bottles were alternated every 2-days to control for
position preferences. Each drinking bottle was weighed every 2-days, and body weights
were recorded every 4-days. An empty cage was used for the placement of dummy bottles
(one ethanol and one water) and fluid lost from each of these bottles was subtracted off the
consumption totals as a control for fluid spillage. A separate set of Mc4r-/- (n = 12) and
Mc4r+/+ (n = 12) mice were tested for voluntary consumption of 0.15% (w/v) saccharin
solution versus water followed by 10% (w/v) sucrose solution versus water in a two-bottle
test. Mice were given access to each sweet solution for 2-days.
Experiment 2: Ethanol Consumption Following Central Infusion of the MCR Agonist MTII
Mice were anesthetized with a cocktail of Ketamine (117 mg/kg) and Xylazine (7.92 mg/kg)
and surgically implanted with a 26-gauge guide cannula (Plastic One, Roanoke, VA) aimed
at the left lateral ventricle, with the following stereotaxic coordinates: 0.2 mm posterior to
bregma, 1.0 mm lateral to the midline, and 2.3 mm ventral to the surface. Mice were allowed
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to recover for approximately 2-weeks before experimental procedures were initiated. After
experimental procedures, cannula placement was verified histologically. I.c.v. infusions
were given in a 1.0 μl volume over a 1-minute period using a 33-gauge injector needle that
extended 0.5 mm beyond that guide cannula. Compounds were administered manually with
a 1 μl Hamilton syringe. The injectors were left in place for an additional 1-minute to allow
for drug diffusion and to minimize vertical capillary action along the injector tract when it
was removed.
After recovery from surgery, animals received 5-days of habituation to 24-hour, 2-bottle
consumption with one bottle containing water and the second bottle containing a solution of
10% (v/v) ethanol. Following habituation to 2-bottle drinking, mice from each genotype
were distributed into groups that were equated based on ethanol consumption measured
during the last 3-days of baseline. On the test day, mice were weighed, and ethanol, water
and food were removed from their cages 2-hours before the beginning of the dark cycle.
Approximately 30- to 15-minutes before the beginning of the dark cycle, mice were given
i.c.v. infusions of a 0.5 (Mc4r-/- mice, n = 11; Mc4r+/+ mice, n = 8) or 1 (Mc4r-/- mice, n =
6; Mc4r+/+ mice, n = 5) μg dose of MTII (Bachem, Torrance, CA) dissolved 0.9% saline, or
an equal volume of 0.9% saline (Mc4r-/- mice, n = 8; Mc4r+/+ mice, n = 7). We have
previously found that the 1 μg dose of MTII was effective in reducing ethanol intake in
C57BL/6J mice (Navarro et al., 2005; Navarro et al., 2003). We chose MTII as we
previously assessed the effects of MTII in Mc3r-/- mice (Navarro et al., 2005) and could thus
make direct comparisons between studies. The 10% ethanol solution, water and food were
returned immediately before the dark cycle. Intake measures were recorded 6 hours later.
Experiment 3: Ethanol Consumption Following Peripheral Administration of the MCR
Agonist MTII
Mc4r-/- and Mc4r+/+ mice received 5-days of habituation to 24-hour, 2-bottle consumption
with one bottle containing water and the second bottle containing a solution of 10% (v/v)
ethanol. Following habituation to 2-bottle drinking, mice from each genotype were
distributed into groups that were equated based on ethanol consumption measured during the
last 3-days of baseline. On the test day, mice were weighed, and ethanol, water and food
were removed from their cages 2-hours before the beginning of the dark cycle.
Approximately 30- to 15-minutes before the beginning of the dark cycle, mice were given an
intraperitoneal (i.p.) injection of a 5 mg/kg dose of MTII dissolved in 0.9% saline (Mc4r-/-
mice, n = 15; Mc4r+/+ mice, n = 14) or an equal volume of 0.9% saline given in a 5 ml/kg
volume (Mc4r-/- mice, n = 15; Mc4r+/+ mice, n = 15). We chose the 5 mg/kg dose of MTII
because it falls between doses (2 and 10 mg/kg) that have been shown to effectively
attenuate feeding behavior (Chen et al., 2000; Choi et al., 2003). The 10% ethanol solution,
water and food were returned immediately before the dark cycle. Intake measures were
recorded 6- hours later.
Experiments 4 and 5: Sucrose and Saccharin Solution Consumption Following Central
Infusion of the MCR Agonist MTII
Surgery for cannula placement and i.c.v. infusion procedures were the same as described in
Experiment 2 above. After recovery from surgery, animals received 5-days of habituation to
24-hour, 2-bottle consumption with one bottle containing water and the second bottle
containing a solution of 10% (w/v) sucrose (Experiment 4) or 0.15% (w/v) saccharin
(Experiment 5). Following habituation to 2-bottle drinking, mice from each genotype were
distributed into groups that were equated based on sweet solution consumption measured
during the last 3-days of baseline. On the test day, mice were weighed, and sweet solution,
water and food were removed from their cages 2-hours before the beginning of the dark
cycle. Approximately 30- to 15-minutes before the beginning of the dark cycle, mice were
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given i.c.v. infusions of a 0.5 μg dose of MTII dissolved 0.9% saline (Experiment 4, n = 8;
Experiment 5, n = 12) or an equal volume of 0.9% saline (Experiment 4, n = 7; Experiment
5, n = 12). The sweet solution, water and food were returned immediately before the dark
cycle. Intake measures were recorded 6 hours later.
Data Analyses
To obtain a measure that corrected for individual differences in body weight, grams of
ethanol or food and milliliters of water or sweet solution consumed per kilogram of body
weight were calculated. Ethanol preference ratios were also calculated by dividing the
volume of ethanol consumed by total fluid (ethanol + water) consumption. Ethanol
consumption data from Experiment 1 were analyzed with a 2 × 6 (genotype × ethanol
concentration) repeated-measures analysis of variance (ANOVA), and saccharin and sucrose
consumption data were analyzed with 2 × 2 (genotype × days) repeated-measures ANOVAs.
Data from Experiments 2 and 3 were analyzed with two-way 2 × 3 (genotype × MTII dose)
mixed-factor ANOVAs. Finally, data from Experiments 4 and 5 were analyzed using one-
way (dose) ANOVAs. Tukey's tests were used for post hoc analyses. All data are presented
as means ± SEM, and the level of significance was set at p < 0.05 in all cases.
Results
Experiment 1: Two-Bottle Consumption of Ethanol and Water
Data showing 24-hour voluntary consumption of ethanol and water and ethanol preference
ratios in Mc4r-/- and Mc4r+/+ mice during 2-bottle testing are presented in Fig. 1. A
repeated-measures ANOVA performed on ethanol consumption data revealed a significant
main effect of ethanol concentration [F(5, 75) = 59.149; p = 0.001], reflecting the increase in
g/kg of ethanol consumed as the concentration of ethanol was increased over the course of
the experiment (Fig. 1A). No other effects were statistically significant. A repeated-
measures ANOVA performed on water consumption data revealed a significant main effect
of ethanol concentration phase [F(5, 75) = 23.685; p = 0.001], reflecting the greater
consumption of water as the concentration of ethanol was increased. Interestingly, there was
a significant main effect of genotype [F(1, 15) = 5.473; p = 0.034], as Mc4r+/+ mice (71.98
± 5.24 ml/kg/24-h) drank significantly more water than Mc4r-/- mice (54.11 ± 5.56 ml/kg/
24-h) over the course of the experiment (Fig. 1B). No other effects related to the water data
were statistically significant. A repeated-measures ANOVA performed on ethanol
preference ratio data revealed a significant main effect of ethanol concentration phase [F(5,
75) = 26.831; p = 0.001], reflecting the reduced preference for ethanol solution relative to
water as the concentration of ethanol was increased (Fig. 1C). Finally, a repeated-measures
ANOVA comparing body weight data at each phase of the experiment revealed that there
were no significant differences in body weight between Mc4r+/+ mice (20.40 ± 1.09 g
average over the course of the experiment) and the Mc4r-/- mice (23.23 ± 1.11 g average
over the course of the experiment).
A repeated-measure ANOVAs performed on saccharin consumption data revealed a
significant effects of days [F(1, 22) = 8.627; p = 0.008] reflecting increased consumption of
0.15% saccharin over days. However, Mc4r-/- mice (289.66 ± 41.32 ml/kg/day) and Mc4r+/+
mice (302.51 ± 35.24 ml/kg/day) did not differ significantly in the volume of saccharin
solution consumed, nor were there any genotype differences in water intake during access to
saccharin. Similarly, a repeated-measure ANOVAs performed on sucrose consumption data
revealed a significant effects of days [F(1, 22) = 80.103; p = 0.001] reflecting increased
consumption of 10% sucrose over days. Mc4r-/- mice (390.50 ± 13.29 ml/kg/day) and
Mc4r+/+ mice (388.00 ± 26.44 ml/kg/day) did not differ significantly in the volume of
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sucrose solution consumed, nor were there any genotype differences in water intake during
access to sucrose.
Experiment 2: Ethanol Consumption Following Central Infusion of the MCR Agonist MTII
Data showing 6-hour consumption measures following i.c.v. infusion of MTII in the Mc4r-/-
and Mc4r+/+ mice are presented in Fig. 2A-C. A two-way ANOVA performed on ethanol
consumption data revealed a significant interaction effect between genotype and MTII dose
[F(2, 39) = 3.739; p = 0.033], but the genotype and MTII dose main effects were not
significant. Post hoc tests showed that while each dose of MTII significantly reduced
ethanol intake relative to control infusion in Mc4r+/+ mice, neither dose tested altered
ethanol intake in the Mc4r-/- mice (Fig. 2A). A two-way ANOVA performed on food intake
data revealed a main effect of genotype [F(1, 39) = 6.854; p = 0.013] and a significant
interaction between genotype and MTII dose [F(2, 39) = 6.747; p = 0.003] (Fig. 2B). Post
hoc tests showed that while MTII was ineffective in Mc4r-/- mice, each dose of the agonist
tested significantly reduced food intake (relative to vehicle treatment) in the Mc4r+/+ mice.
A two-way ANOVA performed on water intake data showed a significant interaction
between genotype and MTII dose [F(2, 39) = 4.147; p = 0.023], but the main effects were
not statistically significant (Fig. 2C). Despite the significant interaction effect, post hoc tests
revealed MTII did not significantly alter water drinking relative to the vehicle treatment in
either Mc4r-/- or Mc4r+/+ mice. A two-way ANOVA performed on ethanol preference ratio
data failed to show any significant effects (data not shown). Finally, a two-way ANOVA
performed to compare body weight of mice in each treatment condition revealed that while
there was a main effect of genotype [F(1, 39) = 10.020; p = 0.003] such that Mc4r+/+ mice
(22.71 ± 0.93 g) weighed less than Mc4r-/- mice (26.667 ± 0.84 g); there was no significant
interaction between genotype and MTII dose suggesting that body weight did not likely
contribute to the genotype × MTII dose interaction effects observed with ethanol
consumption and food intake data. Increased body weight in Mc4r-/- mice has previously
been reported (Huszar et al., 1997; Marsh et al., 1999).
Experiment 3: Ethanol Consumption Following Peripheral Administration of the MCR
Agonist MTII
Data showing 6-hour consumption measures following i.p. injection of MTII in the Mc4r-/-
and Mc4r+/+ mice are presented in Fig. 2D-F. A two-way ANOVA performed on ethanol
consumption data revealed a main effect of MTII dose [F(1, 55) = 17.22; p = 0.001]. Neither
the genotype main effect nor the interaction effect were significant (Fig. 2D). A two-way
ANOVA performed on food intake data revealed a main effect of MTII dose [F(1, 55) =
14.423; p = 0.001], but the genotype main effect and interaction effect did not achieve
statistical significance (Fig. 2E). A two-way ANOVA performed on water intake data failed
to show any statistically significant effects (Fig. 2F). Similarly, a two-way ANOVA
performed on ethanol preference ratio data failed to show any significant effects (data not
shown). Finally, a two-way ANOVA performed to compare body weight of mice in each
treatment condition revealed a main effect of genotype [F(1, 55) = 7.023; p = 0.011] such
that Mc4r+/+ mice (23.38 ± 0.67 g) weighed less than the Mc4r-/- mice (25.89 ± 0.66 g). No
other effects were significant.
Experiments 4 and 5: Sucrose and Saccharin Solution Consumption Following Central
Infusion of the MCR Agonist MTII
Fig. 3 shows data representing 6-h consumption measures during sucrose testing in
Experiment 4 (Fig. 3A-C) and saccharin testing in Experiment 5 (Fig. 3D-F) in C57BL/6J
mice that were given i.c.v. infusion of vehicle or a 0.5 μg dose of MTII. One-way ANOVAs
performed on sucrose, food, and water intake data from Experiment 4 revealed that the 0.5
μg dose of MTII significantly reduced sucrose [F(1, 13) = 8.477; p = 0.012] and food [F(1,
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13) = 6. 456; p = 0.025] intake but did not significantly alter water drinking relative to the
control condition. One-way ANOVAs performed on saccharin, food, and water intake data
from Experiment 5 revealed that the 0.5 μg dose of MTII significantly reduced saccharin
intake relative to the control injection [F(1, 22) = 7.622; p = 0.011], but did not significantly
alter food or water intake.
Discussion
Constitutive deletion of the MC4R was not associated with significant alterations of
voluntary ethanol consumption or consumption of saccharin or sucrose solutions
(Experiment 1). An initial conclusion might be that endogenous MC4R signaling does not
play a critical role in modulating ethanol self-administration. However, developmental
compensation in constitutive knockout mice may mask the contribution of the deleted gene
(Gerlai, 1996; Gerlai, 2001); thus a role for endogenous MC4R signaling in modulating
ethanol drinking cannot be ruled out by null data. Interestingly, consistent with a recent
report implicating MCR signaling in the modulation of water intake (Yosten and Samson,
2010), the present data suggest that endogenous MC4R signaling may play a role in the
modulation of water intake as Mc4r+/+ mice drank more water than Mc4r-/- mice over the
course of Experiment 1. Importantly, i.c.v. infusion of MTII (0.5 and 1.0 μg doses)
significantly reduced 6-hour ethanol consumption and food intake in Mc4r+/+ mice without
significantly altering water drinking, but failed to influence ethanol drinking or feeding in
Mc4r-/- mice (Experiment 2). These observations support previous findings showing that
MTII significantly reduces ethanol intake in C57BL/6J mice (Navarro et al., 2005; Navarro
et al., 2003), and extend the literature by showing that the MC4R is the primary receptor
involved in modulating the protective effects of centrally infused MTII on excessive ethanol
intake. The present findings also replicate previous work demonstrating that central
administration of MTII attenuates food intake (Grill et al., 1998; Hollopeter et al., 1998;
Marsh et al., 1999; Navarro et al., 2005; Navarro et al., 2003; Pierroz et al., 2002) and
requires the MC4R (Marsh et al., 1999). Together, the present work highlights the critical
role of the MC4R in modulating the central pharmacological effects of the MCR agonist
MTII on ethanol intake and feeding. On the other hand, since Mc3r-/- mice showed normal
ethanol drinking and food intake when MTII was centrally infused (Navarro et al., 2005),
the MC3R does not appear to be involved.
Consistent with previous reports (Cettour-Rose and Rohner-Jeanrenaud, 2002; Navarro et
al., 2005; Navarro et al., 2003; Pierroz et al., 2002), here we show the peripherally
administered MTII (5 mg/kg) reduced ethanol drinking and food intake. However, unlike
central administration, when administered peripherally, MTII did not require normal MC4R
expression to suppress feeding or ethanol intake. This conclusion is supported by the
observations that i.p. injection of MTII significantly reduced 6-hour ethanol consumption
and food intake (but not water drinking) with similar effectiveness in Mc4r-/- and Mc4r+/+
mice (Experiment 3). Since the MC4R is necessary for the central actions of MTII, the
present data suggest that the effects of peripherally administered MTII on ethanol drinking
and food intake may be modulated by other MCRs. A possibility is that peripheral MCRs
(other than the MC4R) are involved. In fact, radiolabeled MTII, when given in an
intravenous injection at a dose that attenuated food intake, was evident in the
circumventricular organs but did not readily penetrate the blood-brain barrier in rats (Trivedi
et al., 2003) and a more recent study showed low penetration of peripherally administered
MTII into mouse brain (Hatziieremia et al., 2007). MC immunoreactivity and melanocortin
receptor binding have been observed in peripheral tissues, including the gastrointestinal tract
and the adrenal glands (Dhillo et al., 2005; Saito et al., 1983; Tatro and Reichlin, 1987), and
it is therefore possible that peripherally administered MTII attenuated ethanol consumption
and food intake by actions within these peripheral regions. It should be noted that while a
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previous report showed that an i.p. injection of a 10 mg/kg dose of MTII reduced food
intake in both Mc4r-/- and Mc4r+/+ mice (Chen et al., 2000), a more recent finding showed
that an i.p. injection of a 100 μg dose of MTII failed to alter feeding in Mc4r-/- mice but was
effective in Mc4r+/+ mice (Balthasar et al., 2005). Thus, it is also possible that lower doses
of peripherally administered MTII require the MC4R to reduce food (and ethanol) intake,
while higher doses (such as the 5 mg/kg dose used here) influence ingestive behaviors by
acting on other MCRs. A more comprehensive assessment of the effects of peripherally
administered MCR agonists, over a range of doses, on ethanol intake (as well as possible
non-specific effects) will be the focus of future research.
One goal of the present report was to assess the effects of MTII on the consumption of
various reinforcing stimuli, in addition ethanol and food. I.c.v. infusion of a 0.5 μg dose of
MTII, which significantly reduced 6 hour ethanol drinking and food intake in wild-type
mice, also attenuated 6 hour consumption of a 10% sucrose solution and a 0.15% saccharin
solution without altering water drinking. Thus, the MCR agonist MTII blunts the
consumption of both caloric (ethanol, food and sucrose) and non-caloric (saccharin)
reinforcers, observations which are consistent with the hypothesis that overlapping MC
pathways modulate ethanol consumption and the consumption of natural reinforcers,
regardless of caloric content. In fact, this should not come as a surprise in light of
electrophysiological evidence demonstrating that both drugs of abuse and ‘natural’
reinforcers (food and water) produce similar cell firing in the nucleus accumbens (Carelli et
al., 2000; Hollander et al., 2002; Roitman et al., 2004; Roitman et al., 2005; Roitman et al.,
2008; Roop et al., 2002), and the observation that a growing list of peptides and proteins
modulate both ethanol consumption and food intake (Thiele et al., 2003). For example,
opioid receptor antagonists, which are approved for treating alcoholism, reduce both ethanol
consumption and food intake (Gonzales and Weiss, 1998; Kamdar et al., 2007; Kotz et al.,
1997; Middaugh et al., 2000; Yeomans and Gray, 2002). Interestingly, it has been proposed
that cannabinoid receptor (CB1) agonists may be useful therapeutic agents for treating
obesity (Cota et al., 2003) and alcoholism (Racz et al., 2003), and we suggest that MCR
agonists may also provide a dual therapeutic role.
Given that administration of MTII was associated with reduced consumption of each of the
reinforcing stimuli examined here, one potential concern is that administration of MTII
produces non-specific, and potentially aversive, effects. However, contrary to this
hypothesis is the observation that MTII failed to significantly alter water intake relative to
vehicle treatment in each of the experiments reported here, and we have previously observed
MTII-induced attenuation of ethanol drinking that was not associated with altered water
intake (Navarro et al., 2005; Navarro et al., 2003). Another potential concern is that the
effects of MCR agonists on ethanol drinking may be secondary to alterations of ethanol
metabolism. However, this is unlikely since we have previously shown that peripheral and
central administration of MTII do not alter blood ethanol clearance (Navarro et al., 2005;
Navarro et al., 2003).
Interestingly, while not significant when compared to the vehicle condition, there was a
trend for the 1.0 μg dose of MTII to increase food intake in Mc4r-/- mice in Experiment 2.
MCR agonist-induced increase of food intake has previously been reported in Mc4r-/- mice
and was hypothesized to reflect a compensatory increase of MC3R signaling (Kumar et al.,
2009). Consistent with this idea, a selective MC3R agonist was found to increase food
intake suggesting that the MC3R functions as a presynaptic autoreceptor in brain regions
that modulate food intake (Cone, 2006; Marks et al., 2006).
In conclusion, the present work provides new insight into the mechanism by which MCR
signaling influences ethanol consumption and feeding by demonstrating the essential role of
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central MC4R in modulating MCR agonist-induced reductions of ethanol intake and food
intake. On the other hand, the MC4R does not modulate the effects of peripherally-
administered MCR agonist (MTII) on ethanol and food intake, suggesting that different
populations of MCRs modulate the actions of centrally versus peripherally administered
MTII. Centrally administered MTII also attenuated the consumption of sucrose and
saccharin solutions at a dose that did not alter water drinking, consistent with the hypothesis
that overlapping central MC pathways modulate the reinforcing properties of ethanol and
natural reinforcers, independent of caloric content. Taken together, the present observations
and previous work suggest that MC4R agonists, in addition to being attractive targets for
treating obesity, may have therapeutic value for treating excessive ethanol consumption in
individuals afflicted with alcohol abuse disorders or that are ethanol-dependent.
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Voluntary consumption of 3, 5, 8, 10, 15, and 20 % (v/v) ethanol (panel A), water during
access to different concentrations of ethanol (panel B), and ethanol preference ratios at each
concentration of ethanol (panel C) in Mc4r -/- and Mc4r +/+ mice in the two-bottle testing
study (Experiment 1). All values are means ± SEM. Mc4r +/+ mice drank significantly more
water than Mc4r -/- mice over the course of the experiment as revealed by a significant main
effect of genotype (p = 0.001).
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Consumption of 10% (v/v) ethanol (g/kg/6-h), food (g/kg/6-h), and water (ml/kg/6-h) in
Mc4r -/- and Mc4r +/+ mice given intracerebroventricular infusion of saline (0 μg) or MTII
(0.5 or 1.0 μg) are presented in panels A, B, and C, respectively (Experiment 2). Similarly,
consumption of ethanol, food, and water in Mc4r -/- and Mc4r +/+ mice given intraperitoneal
injection of 0.9% saline (0 mg/kg) or MTII (5 mg/kg) are presented in panels D, E, and F,
respectively (Experiment 3). All values are means ± SEM. * p < 0.05 relative to 0 μg or 0
mg/kg dose.
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Consumption of sweet solution (ml/kg/6-h; panels A and D), food (g/kg/6-h; panels B and
E), and water (ml/kg/6-h; panels C and F) in C57BL/6J mice given intracerebroventricular
infusion of saline (0 μg) or MTII (0.5 μg). Sweet solution was made from 10% sucrose
(Experiment 4; panels A, B, and C) or 0.15% saccharin (Experiment 5; panels D, E, and F).
All values are means ± SEM. * p < 0.05 relative to 0 μg dose.
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